Pacers’ Bennedict Mathurin challenged by Rick Carlisle – ‘opportunity of a lifetime’

Indiana Pacers coach Rick Carlisle calls it an “opportunity of a lifetime” for Bennedict Mathurin after a tough loss to the ...
Shiftdriftdrive on MSN

Would You Daily an M4 CSL?

This car is something else — the BMW M4 CSL delivering raw performance, sharp looks, and a driving feel that stands apart. Built with a clear focus on performance, the M4 CSL shows what happens when ...
Motley Fool Australia

Why CSL shares now look 'massively oversold'

CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and strategic changes. Analyst John Athanasiou from Red Leaf Securities suggests CSL shares are oversold, ...
The Australian

CSL workers walk off the job for 24 hours

Accusing CSL of a “disgraceful” approach to bargaining, the CSL Behring workers are taking the protected action as the company puts out a revised offer to workers following the voting down of a ...
Motley Fool Australia

Should I buy CSL shares in December?

CSL's share price has declined by 35% in 2025, influenced by a challenging US healthcare industry and cautious growth prospects. Despite headwinds, UBS sees potential medium-term recovery, especially ...
The Australian Financial Review

CSL rout hits Australia’s biggest blue-chip investors

Some of Australia’s largest blue-chip investors have been caught on the wrong side of one of the year’s most crowded trades after piling into CSL as an alternative to holding a big position in ...
Bloomberg L.P.

Australia’s CSL to Invest $1.5 Billion in US Drug Manufacturing

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...
FiercePharma

CSL charts US plasma manufacturing expansion with $1.5B investment

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...
Morningstar

Australia's CSL to Expand U.S. Production

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...
The Business Journals

CSL, with big presence in King of Prussia, to invest $1.5B to expand U.S. operations

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...
Bloomberg L.P.

CSL Predicts US Flu-Shot Rebound as Seqirus Expands in Europe

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...